Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2022-02-08 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于子公司收到重组新型冠状病毒变异株疫苗（CHO细胞）境外临床试验伦理批件并获得CEPI资金资助的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about its subsidiary receiving ethical approval for clinical trials of a new vaccine and obtaining funding support. It contains no financial statements, no detailed financial data, no management discussion of financial results, and no regulatory certifications. The document is short (1020 characters) and serves as a notification of a significant corporate event related to research and development and funding. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital/Financing Update since it does not discuss financial results or capital structure changes. It is not a legal proceeding or merger announcement. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a clinical trial approval and funding, which does not fit other specific categories.
2022-02-08 Chinese
关于对外投资成立北京微达生物科技有限公司并完成工商登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company about the establishment of a new investment entity, Beijing Weida Biotechnology Co., Ltd., including details of the investment, registration, and business scope. It does not contain financial statements, audit information, or regulatory certifications. It is not a report or presentation but an announcement of a corporate action related to investment and company structure. This fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2022-01-28 Chinese
关于聘任公司高级管理人员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a senior management personnel (Vice President) at the company. It includes details about the board meeting resolution approving the appointment and confirms compliance with relevant laws and regulations. There is no financial data, no report attached or referenced as being published, and no mention of voting results or other categories. This fits the definition of Board/Management Information (MANG), which covers announcements of changes in senior management.
2022-01-28 Chinese
沃森生物：2021年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2021年度业绩预告' which translates to '2021 Annual Performance Forecast'. It provides estimated financial results for the fiscal year 2021, including net profit and revenue projections, but explicitly states that the data is preliminary, unaudited, and subject to change in the forthcoming full annual report. The document is short (1047 characters) and serves as a performance forecast rather than a full financial report. It also mentions that detailed financial data will be disclosed in the 2021 annual report. This type of document is typically classified as an Earnings Release (ER) because it announces key financial results highlights and forecasts for a fiscal year but is not the full annual report itself. FY 2021
2022-01-28 Chinese
独立董事关于第四届董事会第三十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion regarding the appointment of a senior management member at Yunnan Watson Biotechnology Co., Ltd. It references compliance with laws and company bylaws and confirms the qualifications and approval of the appointment. This is a governance-related announcement about management changes rather than a full report or financial disclosure. It does not contain financial data or detailed management discussion but focuses on board/management personnel changes.
2022-01-28 Chinese
第四届董事会第三十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the board of directors of Yunnan Watson Biotechnology Co., Ltd. It details the resolutions passed at the 31st meeting of the 4th board, including the appointment of a new senior management member and approval of a cooperation agreement. The document includes voting results and references to related announcements on the official disclosure website. It does not contain financial statements or detailed financial analysis, nor is it a transcript or presentation. It is an official announcement of board decisions, specifically about management appointments and business cooperation agreements. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (1309 characters), consistent with an announcement rather than a full report.
2022-01-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.